LONDON - The T-cell cancer immunotherapy bandwagon keeps rolling on, with Cell Medica Ltd. announcing the close of a remarkable £50 million (US$78 million) series B to fund development of its autologous treatment for Epstein-Barr virus (EBV)-related lymphomas. Read More
Intra-Cellular Therapies Inc. enrolled the first patient in one of two planned phase III studies of its lead candidate for the treatment of acutely exacerbated schizophrenia, triggering a $1.5 million obligation to IP partner Bristol-Myers Squibb Co. and positioning itself to deliver the first late-stage results for the drug, called ITI-007, as early as next year's fourth quarter. Read More
LONDON – One of the latest techniques for understanding the structure of the pores that control what can enter and leave cell nuclei involves poking and feeling the molecules inside the pores using a very, very tiny spike of silicon. Read More
LONDON – Midatech Pharma Ltd. is preparing for an initial public offering (IPO) in which it will raise £30 million (US$47 million) to fund phase I development of its gold nanoparticle needle-free insulin delivery system and the expansion of its technology into the targeted delivery of chemotherapy drugs. Read More
SHANGHAI – In its fourth in-licensing deal this year, Yabao Pharmaceutical Co. Ltd., of Suzhou, China, signed a deal with the prestigious MRC Tech, a UK-based nonprofit, to co-develop therapeutics for the treatment of Parkinson's disease. Read More
NEW DELHI – The final leg of a court case that will decide the fate of India's ailing public sector vaccine makers will begin next week. At stake is the survival of struggling public sector units (PSUs), originally created to produce inexpensive vaccines for public vaccination programs. Read More
Oculus Innovative Sciences Inc., of Petaluma, Calif., filed a registration statement with the SEC indicating it plans to offer up to $6 million in common shares and warrants, including overallotments. The offering was not priced. Read More
Pharmamar SA, of Madrid, said Janssen Research & Development LLC, a unit of New Brunswick, N.J.-based Johnson & Johnson, submitted a new drug application (NDA) seeking FDA approval of Yondelis (trabectedin) for use in soft-tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes who have received prior chemotherapy, including an anthracycline. Read More
strong>Amarantus Bioscience Holdings Inc., of San Francisco, disclosed positive effects of mesencephalic-astrocyte-derived neurotrophic factor (MANF) for the protection from vision loss in an animal model of retinitis pigmentosa (RP). Read More
Valeant Pharmaceuticals International Inc., Laval, Quebec, said it received approval from the FDA for Onexton gel (clindamycin phosphate and benzoyl peroxide), 1.2 percent/3.75 percent, for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older. Read More
